

Test Definition: CAVPC

California Virus (La Crosse) Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid

Overview

Useful For Aiding in the diagnosis of California (La Crosse) encephalitis using spinal fluid specimens

Testing Algorithm For more information see <u>Mosquito-borne Disease Laboratory Testing</u>.

Special Instructions

Mosquito-borne Disease Laboratory Testing

Method Name Immunofluorescence Assay (IFA)

NY State Available

Specimen

Specimen Type CSF

Ordering Guidance

This assay detects California virus antibodies only. For a complete arbovirus panel, order ABOPC / Arbovirus Antibody Panel, IgG and IgM, Spinal Fluid.

New York State clients: This test is not offered for specimens originating in New York.

Specimen Required

Container/Tube: Sterile vial Preferred: Vial number 1 Acceptable: Any vial Specimen Volume: 0.8 mL

Forms

If not ordering electronically, complete, print, and send <u>Infectious Disease Serology Test Request</u> (T916) with the specimen.

Specimen Minimum Volume

0.5 mL



California Virus (La Crosse) Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid

Reject Due To

Gross	ОК
hemolysis	
Gross lipemia	ОК

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
CSF	Refrigerated (preferred)	14 days	
	Frozen	14 days	

Clinical & Interpretive

Clinical Information

California (La Crosse) virus is a member of the *Bunyaviridae* family, and it is one of the arthropod-borne encephalitides. It is transmitted by various *Aedes* and *Culex* mosquitoes and is found in such intermediate hosts as the rabbit, squirrel, chipmunk, and field mouse.

California meningoencephalitis is usually mild and occurs in late summer. Ninety percent of infections are seen in children less than 15 years of age, usually from rural areas. The incubation period is estimated to be 7 days, and acute illness lasts 10 days or less in most instances. Typically, the first symptoms are nonspecific, lasting 1 to 3 days, and are followed by the appearance of central nervous system (CNS) signs and symptoms, such as stiff neck, lethargy, and seizures, which usually abate within 1 week. Symptomatic infection is almost never recognized in those over 18 years old. The most important sequela of California virus encephalitis is epilepsy, which occurs in about 10% of children and almost always in patients who have had seizures during the acute illness. An estimated 2% of patients have persistent paresis. Learning disabilities or other objective cognitive deficits have been reported in a small proportion (<2%) of patients. Learning performance and behavior of most recovered patients are not distinguishable from comparison groups in these same areas.

Infections with arboviruses can occur at any age. The age distribution depends on the degree of exposure to the particular transmitting arthropod relating to age, sex, and occupational, vocational, and recreational habits of the individuals. Once humans have been infected, the severity of the host response may be influenced by age. Serious California (La Crosse) virus infections primarily involve children, especially boys. Adult males exposed to California viruses have high prevalence rates of antibody but usually show no serious illness. Infection among males is primarily due to working conditions and sports activities taking place where the vector is present.

Reference Values

IgG: <1:1 IgM: <1:1 Reference values apply to all ages.



Test Definition: CAVPC

California Virus (La Crosse) Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid

Interpretation

A positive result indicates intrathecal synthesis of antibody and is indicative of neurological infection.

Cautions

All results must be correlated with clinical history and other data available to the attending physician.

False-positive results may be caused by breakdown of the blood-brain barrier, or by the introduction of blood into the cerebrospinal fluid at collection.

Clinical Reference

1. Dolin R: California encephalitis, hantavirus pulmonary syndrome, hantavirus hemorrhagic fever with renal syndrome, and bunyavirus hemorrhagic fevers. In Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:2169-2176

2. Piantadosi A, Kanjilal S: Diagnostic approach for arboviral infections in the United States. J Clin Microbiol. 2020 Nov 18;58(12):e01926-19. doi: 10.1128/JCM.01926-19

Performance

Method Description

The indirect immunofluorescent antibody (IFA) assay is a 2-stage "sandwich" procedure. In the first stage, the patient cerebrospinal fluid (CSF) is diluted in Pretreatment Diluent for IgM and phosphate buffered saline (PBS) for IgG, added to appropriate slide wells in contact with the substrate, and incubated. Following incubation, the slide is washed in PBS, which removes unbound CSF antibodies. In the second stage, each antigen well is overlaid with fluorescein-labeled antibody to IgM and IgG. The slide is incubated allowing antigen-antibody complexes to react with the fluorescein-labeled anti-IgM and anti-IgG. After the slide is washed, dried, and mounted, it is examined using fluorescence microscopy. Positive reactions appear as cells exhibiting bright apple-green cytoplasmic fluorescence against a background of red negative control cells. Semi-quantitative endpoint titers are obtained by testing serial dilutions of positive specimens.(Package inserts: Arbovirus IFA IgM and Arbovirus IFA IgG Instructions for Use. Focus Diagnostics; Rev 02, 05/01/2018)

PDF Report

No

Day(s) Performed

May through October: Monday through Friday November through April: Monday, Wednesday, Friday

Report Available

Same day/1 to 4 days

Specimen Retention Time

2 weeks



Test Definition: CAVPC

California Virus (La Crosse) Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid

Performing Laboratory Location

Rochester

Fees & Codes

Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86651 x 2

26366

LOINC[®] Information

Test ID	Test Order Name	Order LOINC [®] Value
CAVPC	Calif(LaCrosse) Encep Ab Panel, CSF	96498-1
Result ID	Test Result Name	Result LOINC [®] Value

Calif(LaCrosse) Encep Ab, IgM,CSF

9540-6